Latest Bare-metal stent Stories
NATICK, Mass., Aug. 3 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of its fourth-generation SYNERGY(TM) Coronary Stent.
WALTHAM, Mass., June 29 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite the rising popularity of drug-eluting stents (DES) across Latin America, bare-metal stents (BMS) will continue to represent a significant portion of the overall coronary stent market through 2014.
VANCOUVER, June 10 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc.
NATICK, Mass., June 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the market launch and first implants of its TAXUS(Â®) Element(TM) Paclitaxel-Eluting Coronary Stent System in the European Union and other CE Mark countries.
NATICK, Mass., May 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark approval for its TAXUSÂ® Element(TM) Paclitaxel-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent (DES) technology.
Study highlights: Non-cardiac surgery performed in patients who had coronary stents implanted within the previous six weeks is associated with an increased risk of heart complications and death. Patients who required stent implantation following a recent heart attack were at greater risk than those who had stents implanted due to chronic disease. The level of risk was similar for patients treated with bare metal stents and drug-eluting stents. DALLAS, May 5 /PRNewswire-USNewswire/ -- Patients...
WALTHAM, Mass., May 5 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, when Abbott Vascular's Xience V and Boston Scientific's Promus entered the Japanese drug-eluting stent market in Q1 2010, both companies picked up share from competitors Medtronic and Cordis. In its peak sales month, Xience V was used in over 50% of drug-eluting stent procedures, and averaged a unit share of just less than 40% for the first...
Patients who can postpone non-cardiac surgery for at least six weeks after receiving a coronary stent are less likely to suffer reduced blood flow to the heart, heart attack and death than those who have surgery sooner.
- totally perplexed and mixed up.